Steinkasserer A, Harrison R, Billich A, Hammerschmid F, Werner G, Wolff B, Peichl P, Palfi G, Schnitzel W, Mlynar E
Sandoz Forschungsinstitut GmbH, Vienna, Austria.
J Virol. 1995 Feb;69(2):814-24. doi: 10.1128/JVI.69.2.814-824.1995.
SDZ NIM 811 is a cyclosporin A analog that is completely devoid of immunosuppressive capacity but exhibits potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity. The mechanism of action of SDZ NIM 811 is clearly different from those of all other anti-HIV agents described so far. In cell-free assays, it is not an inhibitor of reverse transcriptase, protease, integrase, and it does not interfere with Rev or Tat function. SDZ NIM 811 does not down-regulate CD4 or inhibit fusion between infected and uninfected, CD4-expressing cells. p24 production from chronically HIV-infected cells is not impaired either. To elucidate the mode of action of SDZ NIM 811, we performed DNA PCR analysis in HIV-1 IIIB-infected MT4 cells in one cycle of virus replication. The effects of SDZ NIM 811 on the kinetics of viral DNA synthesis, appearance of two-long terminal repeat circles (2-LTR circles), and integration of DNA were studied. SDZ NIM 811 inhibited 2-LTR circle formation in a concentration-dependent manner, which is indicative of nuclear localization of preintegration complexes. Half-maximal inhibition was achieved at 0.17 microgram/ml; this concentration is close to the 50% inhibitory concentrations (0.01 to 0.2 microgram/ml) for viral growth inhibition. As expected, integration of proviral DNA into cellular DNA was also inhibited by SDZ NIM 811. Analysis of the viral particles produced by SDZ NIM 811-treated, chronically infected cells revealed amounts of capsid proteins, reverse transcriptase activity, and viral RNA comparable to those of the untreated control. However, these particles showed a dose-dependent reduction in infectivity (50% inhibitory concentration of 0.028 microgram/ml) which indicates that the assembly process is also impaired by SDZ NIM 811. Gag proteins are postulated to play a role not only in assembly but also in early steps of viral replication, e.g., nuclear localization of the preintegration complex. Recently, it was reported that HIV-1 Gag protein binds to cyclophilin A, the intracellular receptor for cyclosporin A. Interference with Gag-cyclophilin interaction may be the molecular basis for the antiviral activity of cyclosporin A and its analogs.
SDZ NIM 811是一种环孢素A类似物,完全没有免疫抑制能力,但具有强大且选择性的抗1型人类免疫缺陷病毒(HIV-1)活性。SDZ NIM 811的作用机制与目前描述的所有其他抗HIV药物明显不同。在无细胞试验中,它不是逆转录酶、蛋白酶、整合酶的抑制剂,也不干扰Rev或Tat功能。SDZ NIM 811不会下调CD4或抑制感染细胞与未感染的表达CD4细胞之间的融合。慢性HIV感染细胞的p24产生也未受损害。为了阐明SDZ NIM 811的作用方式,我们在病毒复制的一个周期中,对HIV-1 IIIB感染的MT4细胞进行了DNA PCR分析。研究了SDZ NIM 811对病毒DNA合成动力学、双长末端重复环(2-LTR环)出现以及DNA整合的影响。SDZ NIM 811以浓度依赖的方式抑制2-LTR环的形成,这表明整合前复合物的核定位。在0.17微克/毫升时达到半数最大抑制;该浓度接近病毒生长抑制的50%抑制浓度(0.01至0.2微克/毫升)。正如预期的那样,SDZ NIM 811也抑制了前病毒DNA整合到细胞DNA中。对经SDZ NIM 811处理的慢性感染细胞产生的病毒颗粒分析显示,衣壳蛋白、逆转录酶活性和病毒RNA的量与未处理的对照相当。然而,这些颗粒的感染性呈剂量依赖性降低(50%抑制浓度为0.028微克/毫升),这表明组装过程也受到SDZ NIM 811的损害。推测Gag蛋白不仅在组装中起作用,而且在病毒复制的早期步骤中也起作用,例如整合前复合物的核定位。最近,有报道称HIV-1 Gag蛋白与环孢素A的细胞内受体亲环蛋白A结合。干扰Gag-亲环蛋白相互作用可能是环孢素A及其类似物抗病毒活性的分子基础。